FDCSP+ fibroblast predict response to immune checkpoint inhibitors
This seminar will be held using Zoom. Please register here: https://zoom.us/meeting/register/tJEkfuugqjwuHdTBOG4TnuVc_dEq3Jjc9ALE
Immune checkpoint inhibitors produce impressive clinical benefits in cancer types previously considered untreatable, such as metastatic melanoma. However, only some patients benefit from the treatment, for reasons that remain largely unknown. By conducting a large reanalysis of bulk and single-cell RNA sequencing data we uncovered that a specific population of FDCSP+ fibroblasts might predict response to cancer immunotherapy independently of T cells, B cells or tumour mutational burden, thus opening new avenues to explain why some patients do not respond to immune checkpoint inhibitors.
Date: 30 November 2020, 12:00 (Monday, 8th week, Michaelmas 2020)
Venue: Kennedy Institute of Rheumatology, Headington OX3 7FY
Venue Details: This seminar will be held using Zoom. Please register here: https://zoom.us/meeting/register/tJEkfuugqjwuHdTBOG4TnuVc_dEq3Jjc9ALE
Speaker: Dr Daniele Biasci (University of Cambridge)
Organising department: Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS)
Organisers: Jennifer Pope (Kennedy Institute of Rheumatology), Professor Irina Udalova (Kennedy Institute of Rheumatology)
Organiser contact email address: jennifer.pope@kennedy.ox.ac.uk
Host: Professor Mike Dustin (Kennedy Institute of Rheumatology)
Part of: Kennedy Institute Seminars
Booking required?: Required
Booking url: https://zoom.us/meeting/register/tJEkfuugqjwuHdTBOG4TnuVc_dEq3Jjc9ALE
Audience: Public
Editor: Jennifer Pope